Retrospective analysis evaluates surgical safety and oncological outcomes of breast conserving surgery in T3/T4 non-inflammatory cancer, suggesting viability of the procedure.
Key Points
To assess the surgical and oncological safety of breast conserving surgery for non-inflammatory, T3/T4 breast cancer after neoadjuvant therapy.
Retrospective analysis of prospectively maintained data from 75 female patients diagnosed from 2017 to 2024.
Evaluation of clinico-pathological characteristics, treatment modalities, and surgical outcomes.
Analysis of rates of pathologic complete response and disease recurrence after neoadjuvant systemic therapy.
57% of patients had T3 lesions, with 43% classified as T4a-c.
Positive surgical margins in 2.6% of cases, with most patients receiving neoadjuvant systemic therapy (84%).
Overall survival rate of 95%, with a significant portion remaining disease-free, despite 13% encountering tumor recurrence.